We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Blood Test to Transform Detection and Diagnosis of Alzheimer’s Disease

By LabMedica International staff writers
Posted on 27 Aug 2024
Print article
Image: The new blood test for Alzheimer’s could change how the disease is detected and diagnosed (Photo courtesy of Shutterstock)
Image: The new blood test for Alzheimer’s could change how the disease is detected and diagnosed (Photo courtesy of Shutterstock)

In the brain of patients with Alzheimer’s Disease, there is a buildup of ‘amyloid plaques’, with abnormal levels of this naturally occurring protein clumping together, disrupting cell function. Currently, amyloid plaques are detected through a lumbar puncture, an invasive procedure, while scans are limited in their availability. Blood tests offer a less invasive, more scalable, and cost-effective alternative. Now, a study has examined the effectiveness of a new blood test that could change the way Alzheimer’s Disease is identified.

In the study, researchers from Trinity College Dublin (Dublin, Ireland) investigated whether a blood test could provide a simpler and more accurate method than lumbar punctures. The blood test, known as plasma p-tau217, identifies amyloid plaques in Alzheimer’s patients. The study utilized biobank samples to compare how effectively this blood test detected amyloid proteins compared to those found in cerebrospinal fluid. The findings, published in the Alzheimer's Research and Therapy journal, showed that the blood test's accuracy was over 90% comparable to that of lumbar punctures.

The study also assessed various threshold levels for the blood test and suggested that its use could potentially eliminate over half of the lumbar punctures currently performed. This reduction could reduce the invasiveness and duration of the diagnostic process while also lowering costs. Although lumbar punctures are generally safe and well-tolerated, they can cause side effects like headaches in some patients. Future research aims to replicate these blood test results in diagnostic labs, allowing patients to initially undergo a blood test, thereby bypassing the need for a diagnostic lumbar puncture in clear-cut cases.

“This study found that blood tests such as plasma p-tau217 demonstrate excellent performance to detect the changes that are characteristic of Alzheimer’s disease,” said Dr. Adam Dyer, a Geriatric Medicine Trainee at Tallaght University Hospital and Medical Gerontology, Trinity College Dublin. “In the future, clinical use of these blood tests may enable us to avoid invasive tests such as lumbar punctures in over half of individuals who currently have these procedures performed”. This research is one of a handful in the world to assess this in ‘real-world’ clinical cohorts and the first Irish study to examine the performance of these blood tests.”

Related Links:
Trinity College Dublin

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.